Research from Redeye, Redeye AB

Redeye

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen). 

Expertise in Denmark, Finland, Norway and Sweden.

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Redeye briefly comments on Fluoguide’s Q1 2022 report.</li><li>We believe the company has executed some important milestones during the first five months of 2022, raising capital and presenting solid FG001 safety and efficacy data from part 1 of its phase I/II trial in high-grade glioma.</li><li>We see top-line data from the second part (phase IIb) of Fluoguide’s phase I/II trial in high-grade glioma and its phase II trial in lung cancer as the main remaining catalysts for the stock in 2022.</li></ul>

Redeye briefly comments on Fluoguide’s Q1 2022 report.We believe the company has executed some important milestones during the first five months of 2022, raising capital and presenting solid FG001 safety and efficacy data from part 1 of its phase I/II trial in high-grade glioma.We see top-line data from the second part (phase IIb) of Fluoguide’s phase I/II trial in high-grade glioma and its phase II trial in lung cancer as the main remaining catalysts for the stock in 2022.

Fluoguide

Fluoguide Q1 2022: Our comment